Cohance Lifesciences To Invest USD 18 Mn in NJ Bio, Aruka Bio

New Delhi: Cohance Lifesciences Ltd on Thursday announced an investment of USD 18 million, including USD 13 million in NJ Bio, to strengthen its antibody-drug conjugate (ADC) strategy.

The company, formerly known as Suven Pharmaceuticals, said the USD 13 million additional investment in NJ Bio will increase its common-equity ownership from 56 per cent to 67.3 per cent. The USD 5 million investment in Aruka Bio will provide Cohance a 65 per cent controlling stake in the firm.

Both transactions will be funded through internal accruals, the company said in a release.

The re-organisation aims to integrate NJ Bio’s customer-facing services with Cohance’s manufacturing capabilities to support end-to-end CRDMO development. NJ Bio will remain focused on contract research and manufacturing.

Aruka Bio, a Princeton-based biotech firm, focuses on next-generation ADCs. The investment will fund the buyout of existing shareholders and working capital, positioning Aruka to pursue licensing and collaborations with pharmaceutical partners.

The transactions follow a review of NJ Bio’s performance since December 2024. Completion is expected by the end of September 2026, subject to definitive agreements and customary closing conditions.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)